These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30697879)

  • 1. Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.
    Lund T; Sand C; Gniadecki R; Thomsen SF
    Dermatol Ther; 2019 May; 32(3):e12846. PubMed ID: 30697879
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis.
    Holroyd CR; Parker L; Bennett S; Zarroug J; Underhill C; Davidson B; Armstrong R; Harvey NC; Dennison E; Cooper C; Edwards CJ
    Clin Exp Rheumatol; 2018; 36(1):171-172. PubMed ID: 29352847
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilar medicines for psoriasis. Positioning of the Mexican Academy of Dermatology.
    García-Hidalgo L; Méndez-Flores S; Carrillo-Vázquez S; Estrada-Aguilar L; García-Salazar MDR; Gómez-Flores M; López-Tello A; Charli-Joseph Y; Maldonado-García C; Serrano-Jaén L
    Gac Med Mex; 2020; 156(Supl):1-14. PubMed ID: 32484168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sickness-like disease after switching to biosimilar infliximab.
    Scherlinger M; Schaeverbeke T; Truchetet ME;
    Rheumatology (Oxford); 2017 Nov; 56(11):2032-2034. PubMed ID: 28977481
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.
    Girolomoni G; Feldman SR; Emery P; Ghil J; Keum JW; Cheong SY; Hong E
    Br J Dermatol; 2018 Mar; 178(3):e215-e216. PubMed ID: 29023641
    [No Abstract]   [Full Text] [Related]  

  • 8. SB2: An Infliximab Biosimilar.
    Lamb YN; Scott LJ; Deeks ED
    BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
    Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study.
    Vergara-Dangond C; Sáez Belló M; Climente Martí M; Llopis Salvia P; Alegre-Sancho JJ
    Drugs R D; 2017 Sep; 17(3):481-485. PubMed ID: 28667384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study.
    Giunta A; Manfreda V; Esposito M; Del Duca E; Bianchi L
    Br J Dermatol; 2019 Nov; 181(5):1078-1079. PubMed ID: 31049938
    [No Abstract]   [Full Text] [Related]  

  • 12. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.
    Layegh Z; Ruwaard J; Hebing RCF; L' Ami MJ; van der Weele W; Nurmohamed MT; Krieckaert C; Wolbink G
    Int J Rheum Dis; 2019 May; 22(5):869-873. PubMed ID: 30767391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
    Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Lee Y; Rho YH
    Ann Rheum Dis; 2018 Feb; 77(2):234-240. PubMed ID: 29042358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.
    Fenna J; McCormack D; Kitchen S; Martins D; Gomes T; Tadrous M
    J Manag Care Spec Pharm; 2021 Apr; 27(4):444-452. PubMed ID: 33769851
    [No Abstract]   [Full Text] [Related]  

  • 17. Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis.
    Rho YH; Rychlewska-Hańczewska A; Śliwowska B; Kim TH
    Adv Ther; 2019 Sep; 36(9):2287-2295. PubMed ID: 31372961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Egeberg A; Girolomoni G; Feldman SR; Radtke MA; Carrascosa JM; Ghil J; Keum JW; Lee J; Seo H
    J Drugs Dermatol; 2020 Mar; 19(3):316-318. PubMed ID: 32550686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.
    Pagnini C; Di Paolo MC; De Angelis G; Torcolacci F; Milano M; Trinca D; Porciello R; Graziani MG
    Inflamm Bowel Dis; 2020 Jul; 26(8):e83-e84. PubMed ID: 32458993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.